STING1 and neoplasm: Specifically, stimulation with a STING agonist allowed for a phenotype switch towards an anti-tumor macrophage phenotype, which, in combination with the concomitant enhanced antigen presentation by DCs and infiltration of cytotoxic T lymphocytes (CTLs), inhibited outgrowth of residual tumor (112).